We have to have a reliable income and I think that's dangerous for this country that we're going to lose the next generation of researchers and that this instability is impacting their work towards real life saving innovative and breakthrough discoveries. Cuts to the FDA workforce have added to this chaos, slowing review timelines. and making it more difficult for drug makers and patients to get answers about the approval process for treatments that could bring hope to the rare disease community. (01:35–01:41)
CLAIM
Asserts that FDA workforce cuts have slowed drug review timelines.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
